Indications & Uses
Volidus 0.3 is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Adult Dose: Usually, Voglibose tablets are orally administered in a single dose of 0.2 mg, 3 times a day, before each meal. If the effect is not sufficient, the quantity of a single dose may be increased up to 0.3 mg.Paediatrics: The safety and effectiveness of Voglibose in children has not been established.Geriatrics: Since elderly patients generally have a physiological hypofunction, it is desirable that such caution should be taken as starting the administration at a lower dose (e.g. 0.1 mg at a time). Furthermore, this drug should be carefully administered under close observation, through the course of the disease condition, with careful attention to the blood sugar level and the onset of gastrointestinal symptoms.Dosage in Renal Failure: Voglibose is poorly absorbed after oral doses and renal excretion is negligible, suggesting that no dose adjustment is required. However, pharmacokinetic studies in patients with renal insufficiency are not available.
Side Effects
Vibose unlikely to produce hypoglycaemia in overdose, but abdominal discomfort and diarrhea may occur. Moreover loose stools, abdominal pain, constipation, loss of appetite, urge to vomit (nausea), vomiting, heartburn, increased gas, and intestinal obstruction like symptoms due to increased intestinal gas may cause. Oral hypoglycaemic agents plus Vibose may cause hypoglycaemia (0.1% to <5%), delay in digestion and absorption of disaccharides, fulminant hepatitis, serious liver dysfunction with increased liver enzymes, jaundice, anemia, numbness, edema, blurred vision, hot flushes, malaise, weakness, hyperkalemia, increased pancreatic enzyme (serum amylase).
Cautions & Contraindications
Warnings & Precautions
The administration of Vibose tablets should be limited to patients who have established diabetes as there are certain other disease conditions such as abnormal glucose tolerance and positive urinary sugar that represent diabetes-like symptoms (renal glycosuria, senile abnormal glucose tolerance, abnormal thyroid function, etc.) In patients who are being managed with lifestyle modifications (diet and/or exercise), Vibose must be given only when the 2-hour postprandial blood glucose levels are ≥200 mg/dL. During administration of Vibose, disease progression should be closely observed with monitoring of blood glucose levels at regular intervals. If the effect on postprandial glucose levels is not satisfactory even after the administration of Vibose for 2 to 3 months (postprandial glucose ≥200mg/dL), consider a change to more appropriate treatment. After administration of Vibose, if sufficient control of blood glucose is achieved (postprandial glucose ≤160 mg/dL) and can satisfactorily be maintained with lifestyle therapy or with additional use of oral hypoglycaemic drugs or insulin preparations, the administration of Vibose tablet should be discontinued, and subsequent progresses of disease should be monitored.
Contraindications
Contraindicated in patients with Hypersensitivity to Voglibose or to any of the excipients; Diabetic ketoacidosis, diabetic pre-coma, severe infection, before and after operation or with serious trauma; gastrointestinal obstruction or predisposed to it.